Assessing blood flow in uterine fibroids using intravoxel incoherent motion imaging compared with dynamic contrast-enhanced MRI.

Sainio T, Saunavaara J, Komar G, Viitala A, Otonkoski S, Joronen K, Perheentupa A, Sequeiros RB

Scientific reports23 Jan 2025Cited by 3 (Europe PMC)

PMID39848947PMCIDPMC11758379DOI10.1038/s41598-024-83739-zPepBankPUB-39848947

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

01HumanNot a test of Oxytocin aloneNon-randomized trialOther
In premenopausal women with uterine fibroids, during oxytocin infusion, IVIM perfusion fraction correlated positively with DCE-MRI blood flow (Spearman rho 0.78).
In plain wordsIn women with uterine fibroids, one MRI blood-flow measure matched another measure while oxytocin was infused. Oxytocin was used as a tool.
Peptide
Oxytocin
Outcome
Not applicableCorrelation of IVIM perfusion fraction with DCE blood flow (with oxytocin)
Study
n = 16
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
Spearman rho
0.78
perfusion fraction vs DCE blood flow, with oxytocin
Source sentences
Summary
Statistically significant positive correlations were found between perfusion fraction values and DCE blood flow values with oxytocin (Spearson's ρ = 0.78, p = 0.0004)
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen premenopausal women with uterine fibroids were enrolled in this prospective study.
Summary · context
Pelvic MRI scans were obtained for each subject, both with and without continuous intravenous infusion of oxytocin, known to decrease significantly uterine fibroid blood flow, to assess the changes in blood flow of uterine fibroids.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3984894701
02HumanNot a test of Oxytocin aloneNon-randomized trialOther
In premenopausal women with uterine fibroids, during oxytocin infusion, IVIM fD* correlated positively with DCE-MRI blood flow (Spearman rho 0.64).
In plain wordsIn women with uterine fibroids, a second MRI blood-flow measure also matched the DCE measure while oxytocin was infused. Oxytocin was used as a tool.
Peptide
Oxytocin
Outcome
Not applicableCorrelation of IVIM fD* with DCE blood flow (with oxytocin)
Study
n = 16
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
Spearman rho
0.64
fD* vs DCE blood flow, with oxytocin
Source sentences
Summary
and between fD* values and DCE blood flow values with oxytocin (Spearson's ρ = 0.64, p = 0.0071)
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen premenopausal women with uterine fibroids were enrolled in this prospective study.
Summary · context
Pelvic MRI scans were obtained for each subject, both with and without continuous intravenous infusion of oxytocin, known to decrease significantly uterine fibroid blood flow, to assess the changes in blood flow of uterine fibroids.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3984894702
03HumanNot a test of Oxytocin aloneNon-randomized trialOther
In premenopausal women with uterine fibroids, IVIM perfusion fraction (f) differed significantly between scans with and without oxytocin infusion; the abstract gives no direction.
In plain wordsIn women with uterine fibroids, an MRI blood-flow measure differed between scans with and without oxytocin. The abstract does not state the direction.
Peptide
Oxytocin
Outcome
Direction not reportedIVIM perfusion fraction (f) with versus without oxytocin
Study
n = 16
Comparator
Without oxytocin
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Source sentences
Summary
Significant differences in blood flow were detected across most IVIM parameters: f, D*, and fD* (p < 0.001, p = 0.0027, and p = 0.0002, respectively) when comparing the values without oxytocin and with oxytocin.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen premenopausal women with uterine fibroids were enrolled in this prospective study.
Summary · context
Pelvic MRI scans were obtained for each subject, both with and without continuous intravenous infusion of oxytocin, known to decrease significantly uterine fibroid blood flow, to assess the changes in blood flow of uterine fibroids.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3984894703
04HumanNot a test of Oxytocin aloneNon-randomized trialOther
In premenopausal women with uterine fibroids, IVIM D* differed significantly between scans with and without oxytocin infusion; the abstract gives no direction.
In plain wordsIn women with uterine fibroids, a second MRI blood-flow measure differed between scans with and without oxytocin. The abstract does not state the direction.
Peptide
Oxytocin
Outcome
Direction not reportedIVIM pseudo-diffusion coefficient (D*) with versus without oxytocin
Study
n = 16
Comparator
Without oxytocin
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Source sentences
Summary
Significant differences in blood flow were detected across most IVIM parameters: f, D*, and fD* (p < 0.001, p = 0.0027, and p = 0.0002, respectively) when comparing the values without oxytocin and with oxytocin.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen premenopausal women with uterine fibroids were enrolled in this prospective study.
Summary · context
Pelvic MRI scans were obtained for each subject, both with and without continuous intravenous infusion of oxytocin, known to decrease significantly uterine fibroid blood flow, to assess the changes in blood flow of uterine fibroids.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3984894704
05HumanNot a test of Oxytocin aloneNon-randomized trialOther
In premenopausal women with uterine fibroids, IVIM fD* differed significantly between scans with and without oxytocin infusion; the abstract gives no direction.
In plain wordsIn women with uterine fibroids, a third MRI blood-flow measure differed between scans with and without oxytocin. The abstract does not state the direction.
Peptide
Oxytocin
Outcome
Direction not reportedIVIM fD* with versus without oxytocin
Study
n = 16
Comparator
Without oxytocin
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Source sentences
Summary
Significant differences in blood flow were detected across most IVIM parameters: f, D*, and fD* (p < 0.001, p = 0.0027, and p = 0.0002, respectively) when comparing the values without oxytocin and with oxytocin.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen premenopausal women with uterine fibroids were enrolled in this prospective study.
Summary · context
Pelvic MRI scans were obtained for each subject, both with and without continuous intravenous infusion of oxytocin, known to decrease significantly uterine fibroid blood flow, to assess the changes in blood flow of uterine fibroids.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3984894705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.